Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-VOICE: Comirnaty vaccination in patients with cancer receiving active treatment
2021-000300-38Phase 4Completed
- Sponsor
- Antwerp University Hospital
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Antwerp University Hospital. Primary endpoint: Neutralizing antibody titers against SARS-CoV-2 spike and nucleocapsid proteins at day 28 after second vaccination. Started Jan 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000300-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000300-38.